Ryan B Corcoran

List of Publications by Year
in descending order

72	11,805	66343 42	82547 72
papers	citations	h-index	g-index

76	76	76	17040
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer. Clinical Cancer Research, 2022, 28, 719-727.	7.0	46
2	Cellâ€free human papillomavirus DNA kinetics after surgery for human papillomavirusâ€“associated oropharyngeal cancer. Cancer, 2022, 128, 2193-2204.	4.1	35
3	Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. Cancer Discovery, 2022, 12, 1462-1481.	9.4	30
4	Abstract 5162: TuFEst: a sensitive and cost-effective pan-cancer detection approach with accurate tumor fraction estimation. Cancer Research, 2022, 82, 5162-5162.	0.9	1
5	Abstract LB003: Combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients: Correlative studies from a phase 2 trial. Cancer Research, 2022, 82, LB003-LB003.	0.9	1
6	KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Reports, 2022, 39, 110993.	6.4	34
7	Associations of baseline patientâ€reported outcomes with treatment outcomes in advanced gastrointestinal cancer. Cancer, 2021, 127, 619-627.	4.1	7
8	Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. JCO Precision Oncology, 2021, 5, 123-132.	3.0	30
9	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clinical Cancer Research, 2021, 27, 5586-5594.	7.0	178
10	FGFR2Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discovery, 2021, 11, 2488-2505.	9.4	46
11	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RASâ€“MAPK Reactivation. Cancer Discovery, 2021, 11, 1913-1922.	9.4	243
12	Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss. Oncologist, 2021, 26, e963-e970.	3.7	9
13	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 6343-6353.	7.0	8
14	Spatially organized multicellular immune hubs in human colorectal cancer. Cell, 2021, 184, 4734-4752.e20.	28.9	256
15	Plasma-only ctDNA-Guided MRD Detection in Patients with CRCâ€”Response. Clinical Cancer Research, 2021, 27, 6614-6615.	7.0	4
16	Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nature Cancer, 2021, 2, 1124-1135.	13.2	112
17	Co-occurring Alterations in the RASâ€“MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clinical Cancer Research, 2020, 26, 439-449.	7.0	64
18	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. JCO Precision Oncology, 2020, 4, 1246-1262.	3.0	16

#	Article	IF	Citations
19	Liquid biopsy versus tumor biopsy for clinical-trial recruitment. Nature Medicine, 2020, 26, 1815-1816.	30.7	29
20	Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. Npj Precision Oncology, 2020, 4, 21.	5.4	36
21	Radiomics Texture Features in Advanced Colorectal Cancer: Correlation with BRAF Mutation and 5-year Overall Survival. Radiology Imaging Cancer, 2020, 2, e190084.	1.6	22
22	Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancerâ€"Fact or Fiction?. JAMA Oncology, 2020, 6, 823.	7.1	9
23	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e292-e308.	3.8	3
24	Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspots. Nature Communications, 2020, 11, 2971.	12.8	71
25	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€"Anal Task Forces whitepaper. Nature Reviews Clinical Oncology, 2020, 17, 757-770.	27.6	218
26	BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer. Clinical Cancer Research, 2020, 26, 2466-2476.	7.0	39
27	Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nature Biotechnology, 2020, 38, 420-425.	17.5	48
28	Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clinical Cancer Research, 2020, 26, 1877-1885.	7.0	67
29	Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition. Clinical Cancer Research, 2020, 26, 1633-1643.	7.0	263
30	Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clinical Cancer Research, 2019, 25, 5561-5571.	7.0	64
31	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nature Medicine, 2019, 25, 1415-1421.	30.7	359
32	Cell-free DNA Analysis in Cancer. New England Journal of Medicine, 2019, 380, 501-502.	27.0	12
33	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer. JAMA Oncology, 2019, 5, 1020.	7.1	353
34	Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 207-215.	3.8	17
35	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusionâ€"Positive Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2019, 9, 1064-1079.	9.4	254
36	Targeting Alterations in the RAFâ€"MEK Pathway. Cancer Discovery, 2019, 9, 329-341.	9.4	282

#	Article	IF	Citations
37	Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. Oncologist, 2019, 24, 193-201.	3.7	16
38	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Oncologist, 2019, 24, 1340-1347.	3.7	73
39	Response to Anti-EGFR Therapy in Patients with BRAF non-V600â€“Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2019, 25, 7089-7097.	7.0	79
40	Circulating Tumor DNA: Clinical Monitoring and Early Detection. Annual Review of Cancer Biology, 2019, 3, 187-201.	4.5	6
41	Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discovery, 2018, 8, 428-443.	9.4	448
42	Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. Cancer Discovery, 2018, 8, 417-427.	9.4	61
43	A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. OncoImmunology, 2018, 7, e1423172.	4.6	25
44	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. Cancer Discovery, 2018, 8, 164-173.	9.4	243
45	Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. JCO Precision Oncology, 2018, 2018, 1-15.	3.0	17
46	Therapeutic strategies to target RAS-mutant cancers. Nature Reviews Clinical Oncology, 2018, 15, 709-720.	27.6	274
47	Blood-Based Prediction of Tumor Relapse: The cfDNA Forecast. Cancer Discovery, 2018, 8, 1213-1215.	9.4	3
48	Application of Cell-free DNA Analysis to Cancer Treatment. New England Journal of Medicine, 2018, 379, 1754-1765.	27.0	634
49	Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Medicine, 2018, 7, 2934-2942.	2.8	21
50	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discovery, 2018, 8, 1096-1111.	9.4	256
51	Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusionâ€“Positive Cholangiocarcinoma. Cancer Discovery, 2017, 7, 252-263.	9.4	384
52	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nature Communications, 2017, 8, 1136.	12.8	686
53	Fast-TRKing Drug Development for Rare Molecular Targets. Cancer Discovery, 2017, 7, 934-936.	9.4	9
54	Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy. Genome Medicine, 2017, 9, 37.	8.2	52

#	Article	IF	Citations
55	A combinatorial strategy for treating KRAS-mutant lung cancer. Nature, 2016, 534, 647-651.	27.8	337
56	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Cancer Research, 2016, 76, 4504-4515.	0.9	91
57	Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations. Molecular and Cellular Oncology, 2016, 3, e1048405.	0.7	11
58	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer Discovery, 2016, 6, 147-153.	9.4	338
59	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature Medicine, 2015, 21, 795-801.	30.7	809
60	Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 396-404.	7.0	121
61	Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discovery, 2015, 5, 358-367.	9.4	265
62	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600â€“Mutant Colorectal Cancer. Journal of Clinical Oncology, 2015, 33, 4023-4031.	1.6	430
63	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy inMET-Amplified Esophagogastric Cancer. Cancer Discovery, 2015, 5, 1271-1281.	9.4	162
64	New therapeutic strategies for BRAF mutant colorectal cancers. Journal of Gastrointestinal Oncology, 2015, 6, 650-9.	1.4	21
65	Inhibition of KRAS-Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit. Cancer Discovery, 2014, 4, 452-465.	9.4	169
66	Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models. Cancer Cell, 2013, 23, 121-128.	16.8	343
67	TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma. Science Translational Medicine, 2013, 5, 196ra98.	12.4	124
68	EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib. Cancer Discovery, 2012, 2, 227-235.	9.4	852
69	STAT3 Plays a Critical Role in KRAS-Induced Pancreatic Tumorigenesis. Cancer Research, 2011, 71, 5020-5029.	0.9	358
70	Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. Journal of Clinical Investigation, 2011, 121, 4311-4321.	8.2	177
71	Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers. Oncotarget, 2011, 2, 336-346.	1.8	114
72	BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation. Science Signaling, 2010, 3, ra84.	3.6	314